Studies Presented at American Transplant Congress Support Clinical Utility of TGI’s TruGraf® Tests for Management of Kidney Transplant Recipients Mansfield, MA, June 12, 2018 (GLOBE NEWSWIRE) -- Last week Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes, presented data at the...

Clinical Utility Study Indicates Potential for TruGraf™ Test to Replace Surveillance Biopsies in Kidney Transplant Recipients with Stable Renal Function Mansfield, Nov. 28, 2017 (GLOBE NEWSWIRE) -- MANSFIELD, MA – Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes, has published a...

Study Shows TruGraf Blood Test Enables Non-invasive Detection of Immune Quiescent Kidney Transplant Recipients Mansfield, Oct. 24, 2017 (GLOBE NEWSWIRE) -- MANSFIELD, MA – Transplant Genomics Inc. (TGI), a molecular diagnostics company committed to improving organ transplant outcomes, announces a publication...

U.S. patent issues for gene expression profiles associated with chronic kidney allograft rejection, licensed exclusively to Transplant Genomics Inc Mansfield, MA, Sept. 29, 2017 (GLOBE NEWSWIRE) --   U.S. patent issues for gene expression profiles associated with chronic kidney allograft rejection, licensed exclusively to Transplant Genomics...